Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
4 Cards in this Set
- Front
- Back
|
STATINS IN
CLINICAL USE IN 2009: STRUCTURE LOVASTATIN PRAVASTATIN PRODRUGS; ACTIVE DRUGS SIMVASTATIN FLUVASTATIN ATORVASTATIN ROSUVASTATIN |
MECHANISM OF ACTION
OF THE STATINS 1) INHIBITION OF CHOLESTEROL BIOSYNTHESIS 2)REDUCED INTRACELLULAR CHOLESTEROL 3) INCREASED LDL RECEPTOR ACTIVITY ENHANCING LDL CLEARANCE |
|
|
BILE ACID SEQUESTRANTS:
ANION EXCHANGE RESINS CHOLESTYRAMINE COLESEVELAM COLESTIPOL |
adf
|
|
|
EZETIMIBE:
|
INHIBITOR OF INTESTINAL
CHOLESTEROL ABSORPTION MECHANISMS OF ACTION OF LDL LOWERING DRUGS: EZETIMIBE 1) INHIBITION OF CHOLESTEROL ABSORPTION FROM SMALL INTESTINE 2) REDUCED HEPATIC INTRACELLULAR CHOLESTEROL 3) INCREASED LDL RECEPTOR ACTIVITY ENHANCING LDL CLEARANCE |
|
|
NICOTINIC ACID:
|
MECHANISM OF ACTION
PRIMARY EFFECTS BINDING TO G-PROTEIN COUPLED RECEPTOR - REDUCED cAMP LEVELS -REDUCED HORMONE SENSITIVE LIPASE -REDUCED LIPOLYSIS IN ADIPOCYTES -REDUCED HEPATIC SECRETION OF VLDL REDUCED TRIGLYCERIDE SYNTHESIS VIA INHIBITED ACTIVITY OF DIGLYCEROL ACYL TRANSFERASE-2 |
